1. Volume 61, Issue 3, Pages 577-583 (March 2012)
Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators 
Monique J. Roobol, Heidi A. van Vugt, Stacy Loeb, Xiaoye Zhu, Meelan Bul, Chris H. Bangma, Arno G.L.J.H. van Leenders, Ewout W. Steyerberg, Fritz H. Schröder 
European Urology 
Volume 61, Issue 3, Pages (March 2012)
DOI: /j.eururo
Copyright © 2011 European Association of Urology Terms and Conditions

2. Fig. 1
Areas under the curve of four different models predicting the presence of a biopsy-detectable prostate cancer (PCa) in (A) previously unscreened men, (B) a biopsy-detectable high-grade (HG) PCa in previously unscreened men, (C) the presence of a biopsy-detectable PCa in previously screened/biopsied men, and (D) the presence of a biopsy-detectable HG PCa in previously screened/biopsied men.
BX=biopsy; DRE=digital rectal examination; PNBx=previous negative biopsy; PSA=prostate-specific antigen; RC=risk calculator.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

3. Fig. 2
Box plots of prostate volume assessed by transrectal ultrasound (TRUS) per digital rectal examination (DRE)–assessed prostate volume class.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

4. Fig. 3
Areas under the curve (AUCs) of applying five different models on the validation set of 322 previously screened/biopsied men. (A) AUCs of models predicting the presence of a biopsy-detectable prostate cancer (PCa) in previously screened/biopsied men; (B) AUCs of models predicting the presence of a biopsy-detectable high-grade PCa in previously screened/biopsied men.
Bx=biopsy; DRE=digital rectal examination; PCPT=Prostate Cancer Prevention Trial; PNBx=previous negative biopsy; PSA=prostate-specific antigen; RC=risk calculator.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions